Clinical Trials Browser

Phase 1 × INDUSTRY × veliparib × Clear all

NCT03400306 2021-12-08

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Phase 1 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT01063816 2021-08-02

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1 Completed

79 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01123876 2021-08-02

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1 Completed

60 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02944396 2019-10-23

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02210663 2018-05-07

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Phase 1 Completed

16 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1 Completed

41 enrolled

BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT00649207 2017-11-21

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Phase 1 Completed

80 enrolled

CNS

Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis, Nervous System Neoplasms

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Phase 1 Completed

35 enrolled

Genitourinary

Prostatic Neoplasms

NCT01199224 2017-11-21

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Phase 1 Completed

27 enrolled

Recurrence

NCT01853306 2017-11-21

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Phase 1 Completed

71 enrolled

Tumor-Agnostic

Neoplasms

NCT01589419 2017-11-20

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Phase 1 Completed

32 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT01617928 2017-11-20

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Phase 1 Completed

12 enrolled

Other solid neoplasm

Solid Tumors

NCT02009631 2017-11-20

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Phase 1 Completed

45 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02483104 2017-11-20

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Phase 1 Completed

9 enrolled

Gynecologic

Ovarian Neoplasms

NCT02033551 2016-09-27

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1 Completed

47 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms